{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:09:40Z","timestamp":1781716180295,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["13N 13341"],"award-info":[{"award-number":["13N 13341"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Positron emission tomography with <jats:sup>68<\/jats:sup>Gallium (<jats:sup>68<\/jats:sup>Ga) labeled inhibitors of fibroblast activation protein (<jats:sup>68<\/jats:sup>Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it is not clear if different acquisition timepoints for <jats:sup>68<\/jats:sup>Ga-FAPI-PET may result in comparable imaging information and if repetitive <jats:sup>68<\/jats:sup>Ga-FAPI-PET imaging may add diagnostic value to single timepoint acquisition for recurrent PDAC. Here we analyzed retrospectively early (20\u00a0min p.i.) and late (60\u00a0min p.i.) <jats:sup>68<\/jats:sup>Ga-FAPI-PET imaging using FAPI-46 of 33 patients with possible recurrence of PDAC concerning detection rates and uptake over time of local recurrences, metastases, inflammatory lesions of the pancreas, cholestatic lesions of the liver and reactive tissue. 33 patients with histologically confirmed PDAC after complete or partial resection of the pancreas and possible recurrence were examined by <jats:sup>68<\/jats:sup>Ga-FAPI-46-PET acquired 20- and 60-min post injection (p.i.) of the radiotracer. FAPI-positive lesions were classified as local recurrences, metastases, inflammatory lesions of the pancreas (ILP), cholestatic lesions of the liver and reactive tissue based on histology, PET- and CT-morphology and clinical information. Lesions were contoured, and standardized uptake values (SUVmax and SUVmean) and target-to-background ratios (TBR) were analyzed for both acquisition timepoints. In total, 152 FAPI-positive lesions (22 local relapses, 47 metastases, 26 inflammatory lesions of the pancreas, 28 reactive tissues, and 29 cholestatic lesions) were detected. Detection rates for the early and late acquisition of <jats:sup>68<\/jats:sup>Ga-FAPI-46-PET were almost identical except cholestatic lesions, which showed a higher detection rate at early imaging. SUV parameters and TBRs of ILP significantly decreased over time. Cholestatic lesions showed a tendency towards decreasing uptake. All other types of lesions showed relatively stable uptake over time. Early and late acquisition of <jats:sup>68<\/jats:sup>Ga-FAPI-PET results in comparable imaging information in patients with possible recurrence of PDAC. Two timepoint imaging offers additional diagnostic potential concerning differential diagnoses.<\/jats:p>","DOI":"10.1038\/s41598-023-43049-2","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T11:02:51Z","timestamp":1697713371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2157-9333","authenticated-orcid":false,"given":"Jorge","family":"Hoppner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levin","family":"van Genabith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Colbatzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenija","family":"Gutjahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik M.","family":"Glatting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-243X","authenticated-orcid":false,"given":"Manuel","family":"R\u00f6hrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"issue":"9","key":"43049_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: A review. JAMA 326(9), 851\u2013862 (2021).","journal-title":"JAMA"},{"issue":"4","key":"43049_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.hoc.2015.04.003","volume":"29","author":"RF Dunne","year":"2015","unstructured":"Dunne, R. F. & Hezel, A. F. Genetics and biology of pancreatic ductal adenocarcinoma. Hematol. Oncol. Clin. North Am. 29(4), 595\u2013608 (2015).","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"2","key":"43049_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1148\/radiol.2018171670","volume":"287","author":"M Zins","year":"2018","unstructured":"Zins, M., Matos, C. & Cassinotto, C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology 287(2), 374\u2013390 (2018).","journal-title":"Radiology"},{"issue":"1","key":"43049_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-018-1519-2","volume":"54","author":"M Kitano","year":"2019","unstructured":"Kitano, M. et al. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J. Gastroenterol. 54(1), 19\u201332 (2019).","journal-title":"J. Gastroenterol."},{"issue":"2","key":"43049_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00261-018-1765-z","volume":"44","author":"S Huicochea Castellanos","year":"2019","unstructured":"Huicochea Castellanos, S. et al. Detection of recurrent pancreatic cancer: Value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdom. Radiol. (N. Y.) 44(2), 586\u2013592 (2019).","journal-title":"Abdom. Radiol. (N. Y.)"},{"key":"43049_CR6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.253062","author":"M Rohrich","year":"2020","unstructured":"Rohrich, M. et al. Impact of (68)Ga-FAPI-PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.120.253062 (2020).","journal-title":"J. Nucl. Med."},{"issue":"4","key":"43049_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","volume":"49","author":"Y Pang","year":"2022","unstructured":"Pang, Y. et al. Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging 49(4), 1322\u20131337 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"43049_CR8","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","volume":"48","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus, J. et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur. J. Nucl. Med. Mol. Imaging 48(10), 3221\u20133227 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"43049_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RLU.0000000000002914","volume":"45","author":"Y Luo","year":"2020","unstructured":"Luo, Y., Pan, Q., Zhang, W. & Li, F. Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET\/CT. Clin. Nucl. Med. 45(4), 310\u2013311 (2020).","journal-title":"Clin. Nucl. Med."},{"issue":"13","key":"43049_CR10","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel, F. L. et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET\/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 48(13), 4377\u20134385 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"43049_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. (68)Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60(6), 801\u2013805 (2019).","journal-title":"J. Nucl. Med."},{"key":"43049_CR12","unstructured":"Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, et al. Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: Methodological and diagnostic implications for malignant, inflammatory and degenerative lesions. J. Nucl. Med. 2022."},{"issue":"1","key":"43049_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","volume":"63","author":"M Rohrich","year":"2022","unstructured":"Rohrich, M. et al. Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: A translational exploratory study. J. Nucl. Med. 63(1), 127\u2013133 (2022).","journal-title":"J. Nucl. Med."},{"issue":"10","key":"43049_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev, A. et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J. Nucl. Med. 60(10), 1421\u20131429 (2019).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"43049_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"DM Bates","year":"2015","unstructured":"Bates, D. M., Martin, B. & Ben, W. S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67(1), 1\u201348 (2015).","journal-title":"J. Stat. Softw."},{"key":"43049_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05646-z","author":"K Hu","year":"2021","unstructured":"Hu, K. et al. [(18)F]FAPI-42 PET imaging in cancer patients: Optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-021-05646-z (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"43049_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M Rohrich","year":"2021","unstructured":"Rohrich, M. et al. Impact of (68)Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J. Nucl. Med. 62(6), 779\u2013786 (2021).","journal-title":"J. Nucl. Med."},{"issue":"6","key":"43049_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.121.262808","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler, L. et al. Pitfalls and common findings in (68)Ga-FAPI PET: A pictorial analysis. J. Nucl. Med. 63(6), 890\u2013896 (2022).","journal-title":"J. Nucl. Med."},{"key":"43049_CR19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264361","author":"M Lang","year":"2022","unstructured":"Lang, M. et al. Static and dynamic (68)Ga-FAPI PET\/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.122.264361 (2022).","journal-title":"J. Nucl. Med."},{"issue":"10","key":"43049_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4329\/wjr.v7.i10.319","volume":"7","author":"R De Robertis","year":"2015","unstructured":"De Robertis, R. et al. Diffusion-weighted imaging of pancreatic cancer. World J. Radiol. 7(10), 319\u2013328 (2015).","journal-title":"World J. Radiol."},{"issue":"1","key":"43049_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/ijms21010346","volume":"21","author":"P Mayer","year":"2020","unstructured":"Mayer, P. et al. The microarchitecture of pancreatic cancer as measured by diffusion-weighted magnetic resonance imaging is altered by T cells with a tumor promoting Th17 phenotype. Int. J. Mol. Sci. 21(1), 346 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"43049_CR22","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.3390\/cancers14153688","volume":"14","author":"T Einama","year":"2022","unstructured":"Einama, T. et al. Clinical impact of dual time point (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography fusion imaging in pancreatic cancer. Cancers (Basel) 14(15), 3688 (2022).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"43049_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/MNM.0b013e32832bdcac","volume":"30","author":"E Laffon","year":"2009","unstructured":"Laffon, E. et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl. Med. Commun. 30(6), 455\u2013461 (2009).","journal-title":"Nucl. Med. Commun."},{"issue":"5","key":"43049_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2214\/AJR.07.3439","volume":"191","author":"M Imbriaco","year":"2008","unstructured":"Imbriaco, M. et al. Dual-time-point 18F-FDG PET\/CT versus dynamic breast MRI of suspicious breast lesions. Am. J. Roentgenol. 191(5), 1323\u20131330 (2008).","journal-title":"Am. J. Roentgenol."},{"issue":"3","key":"43049_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00259-019-04552-9","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts, I. et al. The role of additional late PSMA-ligand PET\/CT in the differentiation between lymph node metastases and ganglia. Eur. J. Nucl. Med. Mol. Imaging 47(3), 642\u2013651 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"43049_CR26","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1097\/RLU.0000000000001589","volume":"42","author":"S Schmuck","year":"2017","unstructured":"Schmuck, S. et al. Multiple time-point 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: Value of early dynamic and delayed imaging. Clin. Nucl. Med. 42(6), e286\u2013e293 (2017).","journal-title":"Clin. Nucl. Med."},{"issue":"10","key":"43049_CR27","doi-asserted-by":"publisher","first-page":"1069 e1-5","DOI":"10.1016\/j.crad.2016.04.017","volume":"71","author":"Y Nakamoto","year":"2016","unstructured":"Nakamoto, Y. et al. Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET\/CT in the detection of neuroendocrine tumours. Clin. Radiol. 71(10), 1069 e1\u20135 (2016).","journal-title":"Clin. Radiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43049-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:36:40Z","timestamp":1700509000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43049-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43049"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43049-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UH, CK and FLG have filed a patent application for quinoline-based FAP targeting agents for imaging and therapy in nuclear medicine. UH, CK and FLG also has shares of a consultancy group for iTheranostics. No other potential conflicts of interest relevant to this article exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17848"}}